double-digit organ revenu growth idxx investor
day main manag detail lt target call robust
top-line growth next five year accompani oper margin
expans bp driven highli profit recur revenu
stream revenu price ref lab effici direct
sale effort fuel ep growth consist previou lt
view upsid could stem greater penetr exist clinic pipelin
develop leader dognost meaning
margin leverag follow anticip step commerci invest
nt rais target price sever
compel increment driver support organ growth
ahead industri forese futur continu oper
margin leverag even despit increment invest help instil
greater convict lt growth prospect risk demand competit
flag snap prevent driver new ref lab driver
longer pursu fecal snap launch current fecal antigen ref
laboratori offer market expect contribut
increment top-line growth vs prior goal
fecal antigen/fec snap greater adopt prevent
care measur long term driver note lift recur
revenu practic enrol prevent challeng top
practic open new ref laboratori kentucki sept
expand idexx-direct servic provid vet greater flexibl
later pick-up option next-morn result also expand
market opportun target bp ref lab gross
margin expans next year disclosur specif pipelin
candid like limit go forward part respons
zts/abax deal like contribut less unnecessari volatil
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
global leader diagnost point-of-car equip
refer laboratori servic companion anim also
provid system diagnost livestock water qualiti
price aug rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
share gain refer laboratori point-of-car acceler
global expans greater contribut innov new product
launch technolog advanc greater expect
growth broader anim health industri fundament
stronger expect macroeconom fx headwind
increasingli global footprint less adoption/tract futur product
launch deterior veterinari health fundament
manag highlight sustain market leadership posit double-digit
organ growth trajectori expand instal base diagnost equip new
test capabl broaden geograph footprint matur commerci strategi
advanc technolog capabl help fuel ep
growth next sever year
ep estim remain unchang earth-shatt develop
adjust model confid clearli higher longer term growth
prospect traction expand innov portfolio build leverag
increasingli cohes platform matur commerci footprint
relev increment disclosur investor day includ
global dognost frontier market today potenti
continu key compon growth recur revenu
compound-annual-growth-rate dognost woefulli under-penetrated sizeabl
greenfield upgrad placement opportun continu view well
posit health vet backdrop abil outperform
econom environ continu driver innov expand instal
base geograph expans
sustain lt momentum consist growth target
detail long term guidanc disclos product-by-product annual revenu bridg
achiev organ top-line growth next five year in-lin last year
disclos rang includ revenu growth greenfield
opportun associ new product last year detail
revenu bridg see figur note disclosur product pipelin
limit go forward like attribut new competit dynam
zts/abax contribut less unnecessari intra-quart year volatil
us dognost adopt highli penetr term diagnost util
chemistri panel perform clinic veterinari visit us vs
disclos metric could reach consist top
account next sever year leverag data expand direct
sale footprint drive greater exist custom util
flat fecal snap longer pursu fecal snap launch
current fecal antigen ref laboratori offer market expect
contribut increment top-line growth vs prior goal
fecal antigen/fec snap also open new refer
laboratori kentucki sept expand idexx-direct servic provid
vet greater flexibl later pick-up option next-morn result also
expand market opportun target bp ref
laboratori gross margin expans next five year
sdma slide launch prevent care upsid sdma continu drive
refer laboratori growth million test run date expect
contribut top-line growth next five year moreov recent
launch in-hous offer drive consum growth catalyst user
alreadi purchas sinc launch follow-on test refer
laboratori in-hous offer potenti upsid importantli prevent care
repres attract opportun vet practic administ
prevent care check-up grow total revenu vs industri
sedivu consum util still fledgl stage sinc launch earli
expand sedivu global instal base instrument
also drive increment stream high-margin durabl recur revenu gener
million revenu recent quarter remain confid
prospect expect sedivu drive top-line growth
placement utilization/instru remain rel low
moreov highlight competit greenfield potenti
sedivu placement america
util level growth us clinic five year ago
rise acceler rate sinc implement direct distribut strategi
sale effort behind competit servic offer also
help broader test menu launch sdma fecal antigen
importantli signific cross-sel opportun remain custom
current use in-hous refer lab test modal albeit
pet-tech advantag increasingli cohes advanc system
connect remain key differenti sourc growth activ
practic util solut note invest well million
softwar data technolog past three year order broaden
deepen portfolio
highlight segment acquir year ago idexx water
test segment maintain presenc countri around world
million revenu next five year forecast
constant currenc compound-annual-growth-rate driven volum new custom addit
price realiz legiolert addit type test
like take time develop note busi compris recur
revenu virtual custom loyalti importantli also high-margin
oper margin leverag despit step commerci invest near term
target oper margin expans bp cc beyond
driven rise highly-profit recur revenu stream repres
impress revenu price realiz enhanc refer
laboratori product segment gross profit margin expans bp
sourcing/manufactur initi along capit alloc
leverag fuel long term ep growth five-year
charl martineau univers toronto figur driver revenu
figur driver revenu segment
note estim midpoint full year guidanc rang earn releas
state veterinari industri robust fundament backdrop
advanc diagnost innov special therapeut new technolog
increasingli business-savvi veterinarian healthier economi continu drive
strengthen practic revenu test volum also highlight pet owner
willing spend pet millenni demonstr greatest willing
spend pet vs gener cohort us veterinary-rel spend
outpac broader person consumpt
expenditur notabl resili even tougher econom environ
credit suiss estim us bureau econom analysi
emphas evolv pet-human dynam highlight variou metric support
rise spend per pet opportun increas diagnost adopt global
accord recent studi human-anim bond research institut habri
pet owner couldnt imagin give pet reason
bankshot note posit industri trend also repres relev read
broader anim health coverag univers meaning companion anim
exposur includ zoeti distributor henri
schein petx
includ extra sell day
vca store sale
figur driver dx revenu
grow base sophist diagnost equip catalyst dx one sedivu
procyt drive profit consum util come year
help abil increas requisit per patient real-tim care initi
prevent care follow-on test servic leverag sizeabl data trove
associ evidence-bas medicin note place catalyst
greenfield competit account north america vs
importantli term diagnost util chemistri panel perform
clinic veterinari visit us albeit metric could reach
consist idxx top custom next sever year help
support us revenu us continu exceed
underli diagnost market growth repres one fastest grow
segment anim
figur clinic visit includ chemistri panel
top current catalyst instal base estim
competit placement vettest upgrad
greenfield opportun repres meaning runway
instal base expans larg consist previou disclosur
analyz
custom
commit innov
past five year spent nearli repres
 spend dognost industri well ahead next largest competitor
zoetis/abaxi million specif focus novel test new
technolog partnership intern innov effort
updat potenti innov flagship catalyst platform emphas
continu innov across test modal well data system
sdma slide sdma continu drive refer laboratori growth
million test run date via refer laboratori offer drive bp ref lab
growth combin dsma slide expect contribut
top-line growth next five year interestingli conduct analysi
sdma prevent care bloodwork bloodwork done healthi pet conclud
seemingli healthi pet oftentim signific abnorm one
five senior moreov sdma continu sensit chem cbc
creatinin detect signific indic prevent care bloodwork
non-wel test senior importantli prevent care
repres attract opportun vet practic administ
prevent care check-up grow total revenu vs industri averag
sedivu ramp sinc launch earli expand global
instal base instrument also drive increment stream high-margin
durabl recur revenu gener million revenu
recent quarter moreov highlight competit
autom analysi result three minut five drop urin
integr cohes framework sedivu captur digit
convent method note rapid point-of-car inher import urin
test given inher instabl sampl test need within
minut collect today veterinari practic typic perform urin
test per day due limit convent analysi repres million
automat priorit
accur read
highlight fecal antigen recent disclos pursu fecal
snap product remain bullish fecal antigen opportun refer
assum million test run north america less
fecal test run today benefit fecal antigen technolog anticip
top-line growth contribut product alon next five year vs
contribut fecal antigen fecal snap
highlight studi sponsor cornel nc state unveil
american societi rickettsiolog annual meet late june identifi superior
perform idxx snap rapid assay vs abaxiss recent acquir
zoeti recent launch compet test diagnos relev vector-born
diseas acknowledg idxx rapid assay platform high-margin categori
revenu inher vulner competit potenti exacerb
zts/abax transact latest data help instil greater confid idxx
competit posit despit recent abax competit product launch consist
commentari meet manag late june
refer studi test relev vector-born infect includ lyme
ehrlichia cani ewingii chaffeensi anaplasma phagocytophilium
heartworm result studi demonstr superior sensit idxx test
measur correct identif posit diseas state diseas
categori offer report similar specif correct identif
neg diseas state greater
figur studi test
compani data credit suiss meet american societi rickettsiolog
repres total revenu refer laboratori second largest busi
growth like stem footprint expans global new innov test
sdma market share gain integr platform point-of-car refer
idxx estim us refer laboratori market share grown
five year ago rise acceler rate sinc implement direct
distribut strategi sale effort behind competit servic offer
also help broader test menu launch sdma ad
significantli segment top-line growth importantli signific cross-sel opportun
remain custom current use in-hous refer lab
test modal albeit
vdc
current refer lab custom unit state highlight
ampl runway grow within exist custom base exampl
custom util idexx refer lab urinalysi present opportun
penetr exist custom
charl martineau univers toronto figur number us ref lab custom dx categori
importantli oper effici initi drive meaning profit margin
expans across refer laboratori busi estim bp
gross margin improv test mix fecal antigen name
high margin busi greater util new technolog common system
global sourc logist leverag overal network optim
updat assess intern market opportun rise billion
includ softwar assum standard care match us billion
disclos intern market expand meaning improv
standard care grow pet popul intern market idxx
woefulli
under-penetrated potenti meaning uplift util sizeabl
upgrad vettest instal base greenfield placement opportun along
evolv standard care
dognost adopt
charl martineau univers toronto figur intern constant currenc revenu region
figur driver dx recur revenu
consist forefront innov diagnost test
capabl also integr cohes inform technolog solut veterinari
health overal view idxx innov system connect aspect diagnost
care signific competit advantag
note better monet data trove could sourc growth improv
effici longer term area note autom fulfil leverag
consist previou disclosur recent dial invest commerci
